Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Latvia

Marie Skłodowska-Curie Action · Running

MX-WOUND Transforming chronic wound care with targeted MXene-based antibacterial and regenerative technologies

Coordinator
Latvijas Universitate, Latvia
Runs
1 September 2026 to 31 August 2030
Status
Running
EU funding
€1.6m
Total cost
—
Partners
10 organisations in 7 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101299634

What the project is doing

In the project's own words, from its summary on CORDIS.

The MX-WOUND project aims to revolutionize chronic wound care by developing a first-of-its-kind multimodal antibacterial and regenerative platform powered by MXene nanotechnology. Conventional treatments are increasingly ineffective due to multidrug-resistant infections and insufficient regenerative support. MX-WOUND addresses these challenges by uniting targeted antibacterial therapy, photothermal modulation, and regenerative stimulation into a single, clinically translatable solution.

MXenes, a cutting-edge class of 2D transition metal carbides and nitrides, will be polydopamine-coated and conjugated with MRSA-specific antibodies to ensure highly selective bacterial targeting. Combined with near-infrared light-triggered photothermal therapy, this approach enables rapid pathogen eradication with minimal damage to surrounding tissues. In parallel, electrospun and hybrid-spun nanofibrous scaffolds will be engineered to deliver mesenchymal stem cell-derived secretome, promoting angiogenesis, immune modulation, and tissue repair to accelerate wound closure.

MX-WOUND unites leading academic, clinical, and industrial partners from Europe, Ukraine, and the USA in a highly interdisciplinary network. The project follows a rigorous translational pipeline—MXene synthesis and functionalization, scaffold fabrication, in vitro validation, and preclinical in vivo testing—ensuring robustness, scalability, and clinical relevance. Beyond scientific innovation, MX-WOUND will train a new generation of researchers through cross-sectoral secondments, industry placements, and mentoring.

By integrating nanotechnology, precision photothermal therapy, and regenerative medicine, MX-WOUND will deliver a transformative, antibiotic-free therapy for chronic wounds, improve patient outcomes, and help combat the global threat of antimicrobial resistance.

Topics

Who is involved

OrganisationCityCountryRole
Latvijas UniversitateRigaLatviaCoordinator
Nanospace Technology SroMostCzechiaParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Mb SensografaVilniusLithuaniaParticipant
Vilniaus UniversitetasVilniusLithuaniaParticipant
Instytut Immunologii I Terapii Doswiadczalnej Im Ludwika Hirszfelda PanWroclawPolandParticipant
Uniwersytet Im. Adama Mickiewicza WpoznaniuPoznanPolandParticipant
Materials Research CenterKievUkraineParticipant
Sumy State UniversitySumyUkraineParticipant
Worcester Polytechnic InstituteWorcesterUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI